Anton Gopka graduated with honors from the Moscow State Institute of International Relations (School of International Economic Relations) and got supplementary education in corporate finance as part of the board of directors at Harvard Business School.
He is the dean of ITMO’s Faculty of Technological Management and Innovations, a venture capitalist and an entrepreneur, a co-founder and general partner of ATEM Capital, an American company that manages an investment fund for Life Sciences. Before that, he was a managing partner of a major biotechnology fund in Eastern Europe – a strategic partnership between RUSNANO and Domain Associates with a total budget of $760 million. In the last five years, Anton Gopka made 11 investments in the US business, including four companies on NASDAQ, three approved by FDA, and one sold for a record price (in a deal worth as much as $1.7 billion, or 19 times Tobira's previous market value).
Previously, he was the vice president of Barclays Capital for Russia & CIS and the head of mergers and acquisitions at Sistema, where he supported the largest transactions in the field of new technologies, oil and gas, and banking sectors valued at more than $20 billion in total.
Anton Gopka was part of the board of directors at Tobira Therapeutics, Marinus Pharmaceuticals (NASDAQ: MRNS), Neothetics (NASDAQ: NEOT), CoDa Therapeutics, and many others. He was also a member of the American National Association of Corporate Directors (NACD) and advisory committee of the US National Cancer Institute.
Professional interests and competencies
Investments in Life Science, IPO, M&A, and startups.